查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1694059

PTPN2抑制剂:策略性市场洞察和开发平台的展望-2025年

PTPN2 Inhibitors: Strategic Market Insights & Pipeline Outlook - 2025
出版日期: | 出版商: Mellalta Meets LLP | 英文 100 Pages | 商品交期: 5-7个工作天内

价格
简介目录

多年来，PTPN2 一直被称为 "无法用药" 的标靶。 PTPN2 抑制剂目前正成为免疫疗法中很有希望的候选药物。许多公司正在积极致力于开发这些小分子化合物，这个领域的问题不再是 "是否" 的问题，而是这些化合物 "多快" 才能达到有意义的临床验证。

免疫检查点抑制剂市场规模目前在 2023 年价值 484.2 亿美元，预计到 2030 年将达到 1542.5 亿美元，由于癌症发病率上升、医疗保健支出增加以及检查点抑製剂的使用范围扩大，复合年增长率为 17.9%。

检查点抑制剂（PD-1、PD-L1、CTLA-4）彻底改变了癌症治疗，但该行业现在面临一个新的现实：并非所有肿瘤都有反应。 PTPN2 抑制剂不是阻断细胞表面的受体，而是在细胞内部发挥作用，促进 T 细胞活化。这种细胞内免疫调节可能为标准免疫疗法失败的患者提供新的反应。

ABBV-CLS-484（AbbVie/Calico）目前正在进行晚期实体瘤的临床试验。 AbbVie 和 Calico Life Sciences 扩大了合作，额外投资 10 亿美元，专注于老化和与年龄相关的疾病，包括癌症。勃林格殷格翰以 13 亿美元收购 Nerio Therapeutics，加倍押注 PTPN1 和 PTPN2。

Eilean Therapeutics 收购 Ness Therapeutics，以开发具有更高安全性的一流 PTPN2 抑制剂。 Eilean Therapeutics 扩大与 Expert Systems 的合作，整合人工智慧驱动的药物发现，以加速 PTPN2 抑制剂的开发。

本报告提供全球PTPN2抑制剂市场相关调查，提供市场现状，以及收购，授权及联盟契约，竞争情形，市场机会等资讯。

目录

第1章 报告书概要

第2章 概要

  • PTPN2抑制剂的介绍与作用
  • 关于 PTPN2 抑制剂的潜在担忧
  • PTPN2 抑制剂：肿瘤学中极有前景的标靶
  • PTPN2抑制剂的临床应用

第3章 PTPN2抑制剂开发平台分析

  • 概要
  • 适应症/阶段划分的资产
  • 依开发阶段划分的管道产品
  • PTPN2抑制剂竞争格局
  • 公司和阶段划分的管道产品
  • PTPN2抑制剂临床及监管时间表

第4章 PTPN2抑制剂的收购，授权及联盟契约

  • PTPN2抑制剂的收购，授权及交易价值
  • PTPN2抑制剂的收购，授权(各交易类型，各期总额)
  • 正在开发的有前途的技术

第5章 PTPN2抑制剂开发平台的形势

  • 简介概要
  • 后期阶段的资产比较概要
  • PTPN2抑制剂开发平台药物简介
    • ABBV CLS 579(AbbVie/Calico Life Sciences)
    • ABBV CLS 484(AbbVie/Calico Life Sciences)
    • AB-1015(Arsenal bio)
    • HDM 2010(Hangzhou Zhongmei Huadong Pharmaceutical)
    • PTPN2抑制剂(Eilean Therapeutics)
    • PTPN1/N2抑制剂(Boehringer Ingelheim)
    • 其他

第6章 PTPN2抑制剂的未来展望

第7章 SWOT分析

第8章 附录

简介目录

For years, PTPN2 has been labeled as an "undruggable" target-a challenge too complex, a surface too shallow. But the industry has learned that what was undruggable yesterday becomes tomorrow's breakthrough, and PTPN2 inhibitors are now emerging as a serious contender in immunotherapy. With many companies actively developing these small molecules, the field is no longer about "if" but "how fast" these assets can reach meaningful clinical validation.

The immune checkpoint inhibitors market is currently valued at $48.42 billion in 2023, projected to reach $154.25 billion by 2030, growing at a CAGR of 17.9% due to the rising cancer prevalence, increased healthcare expenditure, and expanding applications of checkpoint inhibitors.

The Science: What Makes PTPN2 Different?

Checkpoint inhibitors (PD-1, PD-L1, CTLA-4) revolutionized cancer care, but the industry is now facing a new reality-not all tumors respond. PTPN2 inhibitors offer an alternative, working inside the cell to enhance T-cell activation instead of blocking receptors on the surface. This intracellular immune modulation could unlock new responses in patients who fail standard immunotherapies.

The Market: A Race for Clinical Validation

Despite their potential, PTPN2 inhibitors are still in early-stage development-but the right players are making big bets:

  • ABBV-CLS-484 (AbbVie/Calico) is in trials for advanced solid tumors. AbbVie and Calico Life Sciences extended their partnership with an additional $1 billion investment, focusing on aging and age-related diseases, including oncology.
  • Boehringer Ingelheim made a $1.3 billion move by acquiring Nerio Therapeutics, doubling down on PTPN1 and PTPN2.
  • Eilean Therapeutics acquired Ness Therapeutics, aiming to develop best-in-class PTPN2 inhibitors with improved safety profiles. Eilean Therapeutics expanded its collaboration with Expert Systems, integrating AI-driven drug discovery to accelerate PTPN2 inhibitor development

Challenges & Development Hurdles

Despite promising therapeutic potential, PTPN2 inhibitors face key development challenges:

  • Unfavorable pharmacokinetics, due to the highly cationic active site and shallow protein surface.
  • Clinical uncertainties, with many candidates in early-stage trials requiring further validation.
  • Need for combination therapies, often tested alongside anti-PD-1 therapies to enhance efficacy.

Market & Pipeline Insights: 2025 Report Highlights

The PTPN2 Inhibitor - Pipeline Analytics 2025 Report by Mellalta Meets provides an in-depth analysis of the market opportunity and competitive landscape across multiple indications, including oncology, cardiovascular, and cognitive disorders.

Key coverage areas include:

  • Competitive Analysis - Breakdown of Companies and Products (Discovery to phase III)
  • Pipeline Drug Profiles - Stages of development, intervention types, clinical trials
  • Clinical Developments - Trials by region, efficacy outcomes, safety considerations
  • Business & Investment Trends - Licensing agreements, funding, and collaborations
  • Strategic Opportunities - Market drivers, challenges, and future outlook
  • Recent and upcoming events

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

  • 2.1. Introduction and Role of PTPN2 inhibitors
  • 2.2. Potential Concern with PTPN2 inhibitors
  • 2.3. PTPN2 inhibitors: A Highly-Potential Target in Oncology
  • 2.4. Clinical Applications of PTPN2 inhibitors

3. PTPN2 INHIBITOR PIPELINE ANALYSIS

  • 3.1. Overview
  • 3.2. Assets by Indication/Phase
  • 3.3. Pipeline Products by Stage of Development
  • 3.4. PTPN2 inhibitor Competitive Landscape
  • 3.5. Pipeline Products by Company and Phases
  • 3.6. PTPN2 inhibitor Clinical & Regulatory Timelines

4. PTPN2 INHIBITOR ACQUISITIONS, LICENSING AND COLLABORATION DEALS

  • 4.1. PTPN2 inhibitor Acquisitions, Licensing and Deal values
  • 4.2. PTPN2 inhibitor Acquisitions, Licensing by Transaction type and total amount size by Phases
  • 4.3. Promising Technologies Under development

5. PTPN2 inhibitor PIPELINE LANDSCAPE

  • 5.1. Profile at Glance
  • 5.2. Late-Stage Assets Comparisons At-a-glance
  • 5.3. PTPN2 inhibitor Pipeline Drug Profiles
    • 5.3.1. ABBV CLS 579 (AbbVie/Calico Life Sciences)
      • 5.3.1.1. Product Profile & Description
      • 5.3.1.2. Collaborations
      • 5.3.1.3. Other Developments
      • 5.3.1.4. Clinical Trials
    • 5.3.2. ABBV CLS 484 (AbbVie/Calico Life Sciences)
      • 5.3.2.1. Product Profile & Description
      • 5.3.2.2. Collaborations
      • 5.3.2.3. Other Developments
      • 5.3.2.4. Clinical Trials
    • 5.3.3. AB-1015 (Arsenal bio)
      • 5.3.3.1. Product Profile & Description
      • 5.3.3.2. Collaborations
      • 5.3.3.3. Other Developments
      • 5.3.3.4. Clinical Trials
    • 5.3.4. HDM 2010 (Hangzhou Zhongmei Huadong Pharmaceutical)
      • 5.3.4.1. Product Profile & Description
      • 5.3.4.2. Collaborations
      • 5.3.4.3. Other Developments
    • 5.3.5. PTPN2 inhibitors (Eilean Therapeutics)
      • 5.3.5.1. Product Profile & Description
      • 5.3.5.2. Collaborations
      • 5.3.5.3. Other Developments
    • 5.3.6. PTPN1/N2 inhibitors (Boehringer Ingelheim)
      • 5.3.6.1. Product Profile & Description
      • 5.3.6.2. Collaborations
      • 5.3.6.3. Other Developments
    • 5.3.7. Others...

6. PTPN2 INHIBITOR FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX